Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tarcidomgen Kimleucel in Large B-cell lymphoma: NCT06593145 Clinical Landscape Report 2026
15 October 2026
NCT06593145 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Hormone Receptor Positive Breast Adenocarcinoma: NCT06590558 Clinical Landscape Report 2026
15 October 2026
NCT06590558 clinical landscape for Hormone Receptor Positive Breast Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Mosunetuzumab in T-cell/histiocyte rich large B-cell lymphoma: NCT06594939 Clinical Landscape Report 2026
15 October 2026
NCT06594939 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Autologous hematopoietic stem cell(Ruijin Hospital) in Diffuse Large B-Cell Lymphoma: NCT06589089 Clinical Landscape Report 2026
15 October 2026
NCT06589089 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Endometrial Carcinoma: NCT06586957 Clinical Landscape Report 2026
15 October 2026
NCT06586957 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PEG-Irinotecan in Triple Negative Breast Cancer: NCT06586866 Clinical Landscape Report 2026
15 October 2026
NCT06586866 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT06604858 Clinical Landscape Report 2026
15 October 2026
NCT06604858 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD70-CAR-T(First Song) in Advanced Renal Cell Carcinoma: NCT06586658 Clinical Landscape Report 2026
15 October 2026
NCT06586658 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HUC-MSC-sEV-001 Nasal Drops(Xuanwu Hospital ) in Alzheimer Disease: NCT06607900 Clinical Landscape Report 2026
15 October 2026
NCT06607900 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Adrenocortical Carcinoma: NCT06607692 Clinical Landscape Report 2026
15 October 2026
NCT06607692 clinical landscape for Adrenocortical Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SNC-109 in Glioblastoma Multiforme: NCT06616727 Clinical Landscape Report 2026
15 October 2026
NCT06616727 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludeoxyglucose F-18 in Renal Cell Carcinoma: NCT06613269 Clinical Landscape Report 2026
15 October 2026
NCT06613269 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.